Fast AZ Tagrisso Approval Springboard For Clovis?

Prescription Drug User Fee Act (PDUFA) action dates have become meaningless at the FDA's Office of Hematology and Oncology Products, which has almost consistently for the past year or two leaped ahead of those timelines and approved cancer medicines well ahead of schedule – the most recent being AstraZeneca PLC's lung cancer drug Tagrisso (osimertinib).

Prescription Drug User Fee Act (PDUFA) action dates have become meaningless at the FDA's Office of Hematology and Oncology Products, which has almost consistently for the past year or two leaped ahead of those timelines and approved cancer medicines well ahead of schedule – the most recent being AstraZeneca PLC's lung cancer drug Tagrisso (osimertinib).

The FDA wasn't due to act on the Tagrisso application until Feb. 6, 2016, but gave its nod to the drug on Nov. 13, granting an accelerated approval of the...

More from Anticancer

Merus Bispecific Impresses In Head And Neck Cancer

 

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By 

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By 

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

More from Therapy Areas